Jagsonpal Pharmaceuticals Limited has made the audio recording of its Q1 FY27 earnings conference call available to investors, providing detailed insights into the company’s financial performance for the quarter ended September 30, 2026. The recording, hosted on the company’s official investor relations portal, allows stakeholders to review management’s commentary on operational results, strategic initiatives, and future outlook beyond the numerical data presented in the statutory financial results. This disclosure ensures equal access to information for all shareholders, aligning with regulatory mandates for transparency in listed entities.

The earnings call was conducted on July 30, 2026, at 2:30 P.M., following an earlier intimation issued by the company on July 22, 2026, which outlined the schedule and subsequent availability of the recording. The release of the audio file is a compliance measure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation requires listed companies to disseminate material information promptly and maintain records of such disclosures for public access.

Key Details of the Earnings Call

The following table outlines the essential details of the earnings conference call:

Investors can access the recording by visiting the dedicated earnings calls page on the Jagsonpal Pharmaceuticals Limited website. The link provided in the exchange filing directs users to https://www.jagsonpal.com/investor-relations/earning-calls/ , where the audio file is hosted alongside other investor communications. The availability of this resource supports informed decision-making by providing a comprehensive view of management’s perspective on the quarter’s performance.

Regulatory Compliance and Filing

The announcement was formally communicated to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Ltd (NSE). The filing was signed by Pratham Rawal, who serves as the Company Secretary and Compliance Officer for Jagsonpal Pharmaceuticals Limited. The digital signature on the document confirms the authenticity of the disclosure, with a timestamp of July 30, 2026, at 17:13:45 +05'30'.

This procedural step ensures that all market participants have access to the detailed discussions held during the earnings call. The recording may include insights into operational performance, strategic initiatives, and future outlook that are not fully captured in the condensed financial statements. By making the recording publicly available, the company adheres to the regulatory framework’s emphasis on transparency and equal information dissemination.

Jagsonpal Pharmaceuticals has fixed Friday, September 04, 2026, as the record date to determine member entitlement for the dividend declared for the financial year ended March 31, 2026. This action follows the Board of Directors' recommendation on April 27, 2026, of a dividend of ₹4 per equity share, representing a 200% payout on the face value of ₹2. The distribution is contingent upon final approval by shareholders at the company's 47th Annual General Meeting (AGM).

The AGM is scheduled for Friday, September 18, 2026, at 03:30 p.m. (IST). In compliance with circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India (SEBI), the meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM). Shareholders holding equity shares on the specified record date will be eligible to receive the dividend if the resolution passes.

Dividend Details

The following table outlines the key parameters of the proposed dividend distribution:

Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Jagsonpal Pharmaceuticals issued this intimation to the BSE Ltd and the National Stock Exchange of India Ltd. The company stated that the dividend, once approved by members at the AGM, will be paid within 30 days from the date of its declaration. Payments will be subject to the deduction of applicable taxes at source.

What the Numbers Show

The proposed dividend represents a significant return to shareholders, with the payout amounting to twice the face value of the equity shares. This high payout ratio suggests strong liquidity or retained earnings position for the firm in FY26. The separation of the record date (September 04) from the AGM date (September 18) provides a clear window for trade settlement, ensuring that investors who acquire shares before the record date are eligible for the distribution, provided the Board's recommendation is ratified by the general body of shareholders.